(Information sent by the signing company)

Last March, the company signed a collaboration agreement with researchers from the Fight Against Infections Foundation and IrsiCaixa for the development of a new oral treatment against COVID-19. The constitution of the new company will speed up the process of synthesis and evaluation of the first molecules while at the same time it will serve as a vehicle to channel the necessary investments to carry out the future stages of clinical development of the future drug

Continuing with the initiative launched last March, at the beginning of September 3CL-Bio was created, born as a spin-out of DevsHealth and with the collaboration of the Fight Against Infections Foundation and IrsiCaixa. The new company will channel and structure the development of a new oral treatment for COVID-19. Last March, DevsHealth decided to start the development of a new treatment against COVID-19 with the collaboration of the Fight Against Infections Foundation. and IrsiCaixa, with a clear objective: to make it an affordable treatment, for oral administration and for outpatient use. This will help mitigate the possible effects at the hospital level of future waves, also protecting those people who, for whatever reason, do not receive the vaccine. According to Dr. Roger Paredes, Head of the Infectious Diseases Service at the Germans Trias Hospital i Pujol and Clinical Director of the Fight Against Infections Foundation, "obtaining a new oral treatment against COVID-19 that has few interactions is essential to help reduce new hospitalizations in an ongoing pandemic." The new partnership, led by DevsHealth is presented as a way to channel and channel the best of public-private partnerships, where public institutions contribute their know-how and knowledge of medical needs, while DevsHealth, apart from the management and direction of the project, contributes its technology in the design and discovery of new anti-infective treatments. 3CLBio will also serve as a vehicle to channel the necessary investments to develop both preclinical and phase I clinical studies of the future treatment. For Dr. Alfons Nonell-Canals, CEO of DevsHealth, "this type of collaboration is a way of bringing together the best of both worlds, on the one hand, the knowledge accumulated by public research and, on the other, the agility provided by a private company and, even more so, in our case, in that we provide technology and the agility of a start-up". As regards the initial financing, apart from the resources and own knowledge contributed by the three entities, there is with the previous experience of the Foundation and of Dr. Clotet, president of the Fight Against Infections Foundation and Territorial Clinical Director of Infectious Diseases (Metro Nord ICS Management). Dr. Clotet has years of experience creating and participating in different spin-offs (AlbaJuna, Aelix Therapeutics, Doole, among others). In these first months, DevsHealth has worked on the development of the first candidate molecules and on the development of the project at the administrative and management level. Always with the support of researchers from the Foundation and IrsiCaixa. Now, with the company already established, the in vitro synthesis and validation stages of the first candidate molecules can begin. The laboratory tasks will be carried out in the group of Dr. Núria Izquierdo-Useros, which during the initial stages of the pandemic already developed and fine-tuned a platform for the rapid testing of new molecules. According to Dr. Izquierdo-Useros, "finding new active molecules will be key to be able to combat new variants that may appear or even to face future coronaviruses." With 3CLBio, the entities intend to carry out a very rapid development, as a result of the experience of the Foundation and IrsiCaixa with COVID and DevsHealth technology, which allows millions of molecules to be designed and tested in a few days, in order to close a phase I and subsequent license within a maximum period of two and a half years. About DevsHealth DevsHealth is a DeepTech company that uses artificial intelligence, data analysis and molecular modeling to accelerate the development of new anti-infective treatments. Thanks to its own technological platform, DevsHealth reduces the risk, time and investment in the development of new antibiotics and antivirals. The company, born in July 2021, aims to make use of technology to improve the health of people. With this objective, the company develops its technological platform and applies it to the development of its own pipeline of new anti-infective treatments.

Contact Contact number: Alfons Nonell-Canals Contact description: Alfons Nonell-Canals Contact phone: 625301493